1) Non-cognitive symptoms of early Alzheimer disease and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Catherine Roe about her paper on non-cognitive symptoms of early Alzheimer disease. Dr. Adam Numis is reading our e-Pearl of the week about cannabidiol in the treatment of epilepsy. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about the topic of NMDA receptor encephalitis. The participants had nothing to disclose except Drs. Burns, Roe, Numis and Dalmau.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Roe receives salary support from the NIH, the Longer Life Foundation, the Charles and Joanne Knight Alzheimer Research Initiative of the Knight Alzheimer's disease Research Center, The Farrell Family Research Fund, and F. Simmons and O. Mohan; receives research support from the Charles and Joanne Knight Alzheimer Research Initiative of the Knight Alzheimer's disease Research Center, the Longer Life Foundation, The Farrell Family Research Fund, and F. Simmons and O. Mohan.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.